Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $593.0 million.

  • Arcus Biosciences' Short-term Investments fell 3322.07% to $593.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $593.0 million, marking a year-over-year decrease of 3322.07%. This contributed to the annual value of $828.0 million for FY2024, which is 3101.27% up from last year.
  • Per Arcus Biosciences' latest filing, its Short-term Investments stood at $593.0 million for Q3 2025, which was down 3322.07% from $663.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Short-term Investments high stood at $900.1 million for Q2 2022, and its period low was $345.2 million during Q3 2021.
  • Its 5-year average for Short-term Investments is $673.4 million, with a median of $700.0 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Arcus Biosciences' Short-term Investments was 38229.07% (2021), while the steepest drop was 3841.95% (2021).
  • Over the past 5 years, Arcus Biosciences' Short-term Investments (Quarter) stood at $351.0 million in 2021, then surged by 128.77% to $803.0 million in 2022, then dropped by 21.3% to $632.0 million in 2023, then soared by 31.01% to $828.0 million in 2024, then dropped by 28.38% to $593.0 million in 2025.
  • Its last three reported values are $593.0 million in Q3 2025, $663.0 million for Q2 2025, and $805.0 million during Q1 2025.